{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-020064","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.544540+00:00","generated_at":"2026-05-25T14:34:31.479762+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"INmune Bio files investor presentation on INKmune phase I/II in prostate cancer - no specific data disclosed","bullets":["Preliminary phase I/II results for INKmune in metastatic castration-resistant prostate cancer highlighted in new investor deck.","No specific efficacy or safety data provided in the 8-K excerpt; full slide content not available.","Presentation focuses on in vivo activation of memory-like NK cells (mlNK) using INKmune."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-020064","json":"https://secwatch.observer/filing/0001213900-25-020064.json","markdown":"https://secwatch.observer/filing/0001213900-25-020064.md","text":"https://secwatch.observer/filing/0001213900-25-020064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/0001213900-25-020064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/ea0233142-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T14:34:31.479762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}